Drug-Induced Liver Toxicity /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Humana,
2018.
|
| Edición: | 1st ed. 2018. |
| Colección: | Methods in Pharmacology and Toxicology,
|
| Materias: |
Tabla de Contenidos:
- Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research
- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery
- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction
- Physicochemical Properties and Structural Alerts
- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans
- An Introduction to DILIsym® Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury
- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities
- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury
- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches
- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing
- Engineered Human Liver Co-Cultures for Investigating Drug-Induced Liver Injury
- Status and Future of 3D Cell Culture in Toxicity Testing
- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design
- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury
- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches
- High Content Screening for Prediction of Human Drug-Induced Liver Injury
- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge
- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI)
- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies
- Hy’s Law and eDISH for Clinical Studies
- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease
- Postmarketing Surveillance of Drug-Induced Liver Injury
- Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties
- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI)
- Immune Mechanisms in Drug-Induced Liver Injury
- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury
- Causality Assessment Methods in Drug-Induced Liver Injury
- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans
- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI)
- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury.